Maternal Screening And Treatment For Group B Streptococcus (GBS) Are Associated With Non-Adherence To Guidelines, False-Negative Results And High Management Costs In The United Kingdom, Italy, France, Spain And Germany

Abstract

A797were incorporated into the Chinese framework with 3 main categories: resource needs (personnel, equipment), related clinical outcomes (antimicrobial resistant rate, mortality), and health economic impact (length of stay, defined daily dose). Main differences from U.S. include: 1) limited/no pharmacist involvement in routine participation in intravenous-to-oral switch programs, antibiotic dose modifications/ discontinuations; 2) inclusion of more economic outcome endpoints of AmSPs (e.g., ICU use, reduced intravenous days due to early switch, hospital onset infection rate, and restricted antimicrobial drugs use); and 3) taking a hospital business case perspective by adding a return-on-investment calculation. ConClusions: This study is the first step to develop a comprehensive AmSP evaluation framework for Chinese hospitals. It will help Chinese hospital decision-makers measure the costs and benefits associated with their specific AmSP and gain a better understanding of their value, thus creating an enhanced engagement in implementing AmSPs.

Poor Adherence to the Screening-Based Strategy of Group B Streptococcus Despite Colonization of Pregnant Women in Greece

“…The adherence level observed in our study was approximately 65%. Compared to other European countries, this is mediocre with the highest rates recorded in France (89–96%) [ 14 ] and the lowest in Germany (22.7%). This low compliance may be justified by the fact that GBS screening in Germany is not covered by health insurance [ 15 ], a problem that does not occur in Greece.…”

Parents experiences of having an infant with early onset group B streptococcus infection

“…Contrary to countries such as Australia and Canada where universal screening for GBS is undertaken, the UK operates a Risk Based Approach and administers IAP to mothers who present with risk factors including pre‐term labor, ruptured membranes for over 18 hr, maternal fever, or a previous known GBS infection (Bevan et al., 2019). In the United Kingdom, 33% of women who passed GBS colonization to their neonate had no risk factors (Iadeluca et al., 2017); however, as GBS is not a stable presence, RCOG (2016) determined that a previous GBS infection would not be indicative of a current GBS infection, although IAP is still routinely administered (Pundir & Coomarasamy, 2016). In the United Kingdom, the National Institute of Health Research commissioned a randomized trial to compare the efficacy of the current risk based strategy and a two‐step screening strategy; however, this has been delayed due to the onset of COVID‐19 pandemic (Gbs3trial.ac.uk, 2020).…”